Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

TCR2 Therapeutics Inc. (TCRR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.8600-0.1000 (-5.10%)
At close: 04:00PM EDT
1.9500 +0.09 (+4.84%)
After hours: 04:19PM EDT
Advertisement

TCR2 Therapeutics Inc.

100 Binney Street
Suite 710
Cambridge, MA 02142
United States
617 949 5200
https://www.tcr2.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees139

Key Executives

NameTitlePayExercisedYear Born
Dr. Garry E. Menzel M.B.A., Ph.D.Pres, CEO & Director916.8kN/A1964
Dr. Patrick A. Baeuerle Ph.D.Founder & Member of the Advisory Board47.02kN/A1958
Mr. Peter OlagunjuChief Technical Officer307.42kN/A1978
Dr. Alfonso Quintas Cardama M.D.Chief Medical Officer668.6kN/A1971
Mr. Richard RoombergVP of Corp. ControllerN/AN/AN/A
Mr. Eric M. Sullivan CPAChief Financial OfficerN/AN/A1980
Carl MauchSr. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Margaret Siegel J.D.Head of Legal & Corp. Sec.N/AN/AN/A
Dr. Angela Justice Ph.D.Chief People OfficerN/AN/A1974
Dr. Rosemary Harrison Ph.D.Chief Bus. & Strategy OfficerN/AN/A1983
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

TCR2 Therapeutics Inc.’s ISS Governance QualityScore as of September 1, 2022 is 8. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement